Cingulate Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
(Mark One)
For the fiscal year ended December 31,2025
OR
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|
For the transition period from ________ to ________
Commission file number:001-40874
(Exact name of registrant as specified in its charter)
| Delaware | 86-3825535 |
|---|---|
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| 1901 W. 47th Place Kansas City, KS | 66205 |
| (Address of principal executive offices) | (Zip Code) |
(913) 942-2300
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered |
|---|---|---|
| Common Stock, par value $0.0001 per share | CING | The Nasdaq Stock Market LLC (Nasdaq Capital Market) |
| Warrants, exercisable for common stock | CINGW | The Nasdaq Stock Market LLC (Nasdaq Capital Market) |
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐No ☒
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by checkmark whether the registrant is a large accelerated filer, an accelerate filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
|---|---|---|---|
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| Emerging growth company | ☒ | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No☒
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant computed by reference to the closing price of the registrant’s common stock on June 30, 2025 was approximately $19.4 million. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.
The number of shares outstanding of the registrant’s common stock, par value of $0.0001 per share, as of March 13, 2026 was 11,628,613.
DOCUMENTS INCORPORATED BY REFERENCE
None.
Annual Report on Form 10-K
For the Year Ended December 31, 2025
| Page | ||
|---|---|---|
| PART I | ||
| Item 1 | Business | 4 |
| Item 1A | Risk Factors | 44 |
| Item 1B | Unresolved Staff Comments | 96 |
| Item 1C | Cybersecurity | 96 |
| Item 2 | Properties | 96 |
| Item 3 | Legal Proceedings | 96 |
| Item 4 | Mine Safety Disclosures | 96 |
| PART II | ||
| Item 5 | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 97 |
| Item 6 | [Reserved] | 97 |
| Item 7 | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 97 |
| Item 7A | Quantitative and Qualitative Disclosures About Market Risk | 110 |
| Item 8 | Financial Statements and Supplementary Data | 110 |
| Item 9 | Changes in and Disagreements With Accountants on Accounting and Financial Disclosure | 110 |
| Item 9A | Controls and Procedures | 110 |
| Item 9B | Other Information | 110 |
| Item 9C | Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | 110 |
| PART III | ||
| Item 10 | Directors, Executive Officers and Corporate Governance | 111 |
| Item 11 | Executive Compensation | 115 |
| Item 12 | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 122 |
| Item 13 | Certain Relationships and Related Transactions, and Director Independence | 124 |
| Item 14 | Principal Accountant Fees and Services | 125 |
| PART IV | ||
| Item 15 | Exhibits and Financial Statement Schedules | 126 |
| SIGNATURES | 128 | |
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
This annual report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions intended to identify statements about the future. These statements speak only as of the date of filing this annual report with the SEC and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements include, without limitation, statements about the following:
| ● | our ability to maintain compliance with the continued listing requirements of The Nasdaq Stock Market LLC (“Nasdaq”); |
| ● | our ability to obtain approval for CTx-1301 and the timing of any such approval; |
| ● | our lack of operating history and need for additional capital; |
| ● | our plans to develop and commercialize our product candidates; |
| ● | the timing of our planned clinical trials for our product candidates; |
| ● | the timing of our New Drug Application (“NDA”) submissions for our product candidates; |
| ● | the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; |
| ● | the clinical utility of our product candidates; |
| ● | our commercialization, marketing and manufacturing capabilities and strategy; |
| ● | our ability to identify strategic partnerships; |
| ● | our expected use of cash; |
| ● | our competitive position and projections relating to our competitors or our industry; |
| ● | our ability to identify, recruit, and retain key personnel; |
| ● | the impact of laws and regulations; |
| ● | our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2021 (the “JOBS Act”); |
| ● | our plans to identify additional product candidates with significant commercial potential that are consistent with our commercial objectives; and |
| ● | our estimates regarding future revenue and expenses. |
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. You should refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of this annual report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. We operate in an evolving environment and new risk factors and uncertainties may emerge from time to time. It is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in this annual report will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. You should review the factors and risks and other information we describe in the reports we will file from time to time with the SEC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.